Sobi's Q2 2025 Financial Results Reflect Robust Growth and Innovation

Sobi's Q2 2025 Financial Report: A Testament to Growth and Innovation

On July 16, 2025, Swedish Orphan Biovitrum AB (Sobi®) unveiled its financial report for the second quarter of 2025, showcasing significant progress and strong performance within its portfolio. The numbers reflect Sobi's consistent efforts to enhance patient care through innovative treatments while also paving the way for sustained growth.

Impressive Revenue Surge

Sobi reported a total revenue increase of 13%, and 22% at constant exchange rates (CER), reaching SEK 6,175 million compared to SEK 5,442 million from the previous year. A substantial portion of this growth can be attributed to the haematology sector, which saw a remarkable 27% increase at CER, bringing in SEK 4,570 million versus SEK 3,866 million from the same period last year.

Among the key contributors to this robust performance was the recent launch of Altuvoct, generating SEK 627 million in revenue. In addition, strong sales of Doptelet accounted for SEK 1,220 million, and Aspaveli/Empaveli sales reached SEK 304 million, albeit with a slight decline in sales for Vonjo, which reported SEK 302 million compared to SEK 347 million the previous year.

Immunology Sector Steady Growth

In the immunology segment, Sobi experienced an 11% rise at CER, recording a revenue of SEK 1,288 million compared to SEK 1,277 million during the same quarter last year. This growth was primarily driven by increased sales of Gamifant, which amounted to SEK 632 million, and Kineret, which saw sales reach SEK 749 million.

Additionally, Sobi's strategic portfolio experienced remarkable growth of 65% at CER, contributing SEK 3,384 million to the overall revenue, up from SEK 2,224 million the previous year. This expansion reaffirms Sobi's commitment to innovation and developing valuable treatment options for patients with rare diseases.

Financial Metrics and Operational Efficiency

The adjusted EBITA margin increased to 34%, up from 28% in the previous year. Excluding items affecting comparability (IAC), which amounted to SEK -237 million due to restructuring costs related to organizational changes, EBITA reached SEK 1,863 million, corresponding to a margin of 30% compared to 27% last year.

The reported EBIT stood at SEK 1,010 million, marking a solid increase from SEK 612 million in the previous year. Furthermore, earnings per share (EPS) before dilution were SEK 1.85, significantly higher compared to SEK 0.66 the previous year, while adjusted EPS before dilution rose to SEK 2.38 from SEK 0.72.

Sobi reported a cash flow from operating activities of SEK 1,448 million, down from SEK 2,329 million in the same quarter last year. Despite this, the outlook for 2025 remains positive, anticipating a high single-digit percentage revenue growth at CER and an adjusted EBITA margin projected to be in the mid-30s percentage of revenue.

Conference Call and Investor Relations

Sobi invites investors, analysts, and the media to participate in a conference call on the same day at 14:00 CEST (1300 GMT, 0800 EST) to discuss the latest results. The presentation will include a comprehensive overview of the results along with a Q&A session. Interested parties can follow the presentation live on the Sobi website or access the slides that will be available prior to the call.

For those looking to take part in the call, dialing details for various countries have been provided, showcasing Sobi's commitment to maintaining transparent communication with its stakeholders.

Conclusion

Sobi's Q2 2025 report illustrates the company's ongoing commitment to innovation and excellence in treating rare diseases. With strong revenue growth across its key segments and strategic investments in its portfolio, Sobi looks well-positioned for future success in the biopharma landscape. As it continues to unveil new treatments and expand its market presence, stakeholders will watch closely to see how Sobi navigates the challenges and opportunities that lie ahead.

For more information about Sobi, visit sobi.com.